Petvivo Holdings, Inc. (PETV) Stock Price & Analysis
Petvivo Holdings, Inc. (PETV) rose 2.86% to USD 0.72 as of July 25, 2026 at 09:36 UTC, according to Nexqual real-time market data.
PETV last closed at USD 0.7; the session ranged USD 0.7–0.72 on volume of 2,400 shares. Market capitalization is $27.07M, with a 52-week range of USD 0.6–1.69 (OQX). Source: Nexqual, July 25, 2026 at 09:36 UTC.
Key Statistics (as of July 25, 2026 at 09:36 UTC)
| Price | USD 0.72 |
|---|---|
| Change | ▲ 2.86% (up) |
| Previous Close | USD 0.7 |
| Open | USD 0.72 |
| Day Range | USD 0.7 – 0.72 |
| 52-Week Range | USD 0.6 – 1.69 |
| Volume | 2,400 shares |
| Market Cap | $27.07M |
| Exchange | OQX |
Technical Analysis (PETV)
Nexqual's technical model rates PETV "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 09:36 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.79 (neutral) |
| vs SMA50 | Below (USD 0.79) |
| MACD | -0.02 (negative) |
Analyst Ratings (PETV)
Wall Street analysts rate PETV "None", per Nexqual as of July 25, 2026 at 09:36 UTC.
| Consensus Rating | None |
|---|
Earnings (PETV)
| Next Earnings Date | 2026-08-13 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-03-31 | USD -0.14 vs est -0.32 ▲ beat |
Source: Nexqual, July 25, 2026 at 09:36 UTC.
Financials & Fundamentals (PETV)
| Total Revenue | $1.14M |
|---|---|
| Revenue Growth (YoY) | +13.30% |
| Gross Margin | +66.11% |
| Operating Margin | -770.20% |
| Profit Margin | +0.00% |
| ROE | -326.35% |
| Debt / Equity | 17.1 |
| Current Ratio | 1.35 |
| Total Cash | $350,782 |
| Total Debt | $376,158 |
| Free Cash Flow | $344,955 |
Source: Nexqual, July 25, 2026 at 09:36 UTC.
Financial Health Score (PETV)
Nexqual rates Petvivo Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 09:36 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $351K cash, no debt |
| Cash Flow | Strong — FCF $345K, 36% margin |
| Efficiency | Critical — ROE -326%, ROA -78.0% |
Ownership (PETV)
| Insider Ownership | +58.09% |
|---|---|
| Institutional Ownership | +0.13% |
| Shares Outstanding | 37.59M |
| Float | 28.78M |
| Short % of Float | +1.00% |
Source: Nexqual, July 25, 2026 at 09:36 UTC.
Leadership (PETV)
Petvivo Holdings, Inc. is led by John Lai (age 63), CEO, President & Director, per Nexqual as of July 25, 2026 at 09:36 UTC.
| CEO, President & Director | John Lai (age 63) |
|---|---|
| Chief Financial Officer | Garry N. Lowenthal (age 66) |
| Vice President of Sales & Distributor Relations | Bryan Monninger |
| Vice President of Marketing | Andrea Cranston |
Major Backers & Investors (PETV)
Notable institutional backers of Petvivo Holdings, Inc. include Vermillion Wealth Management, Inc. , according to Nexqual as of July 25, 2026 at 09:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Vermillion Wealth Management, Inc. | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.3% |
Source: Nexqual, July 25, 2026 at 09:36 UTC.
From Petvivo Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-06-29)
Key Strengths & Strategy (as disclosed to the SEC)
- In addition, the FDA and other U.S. regulatory bodies (including the Federal Trade Commission, the Office of the Inspector General of the Department of Health and Human Services, the Department of Justice (DOJ), and various state Attorneys General) monitor the manner in which we promote and advertise our products.
- In addition to the United States patent portfolio, we also have four patents granted in key markets around the world including Canada and countries within the European Union.   We believe we have developed a broad and deep patent portfolio around our biomaterials and manufacturing processes in addition to the application of these biomaterials for use as medical devices, medical device coatings, and pharmaceutical delivery devices.
- We believe our intellectual property portfolio strongly protects our proprietary technology, including the composition of raw elements used to produce our formulations, the fabricated biomaterials, and their application in end products, thereby making our material and devices much more attractive to industry partners.   Furthermore, we rely on proprietary trade secrets and confidential know-how to protect various aspects of its product formulations and manufacturing processes.
- We also strenuously protect our proprietary information and proprietary technology through a combination of contractual arrangements, trade secrets, and patents, both in the United States and abroad.
Partnerships
- In December 2023, the Company entered into a non-exclusive distribution agreement with Covetrus North America, LLC ("Covetrus Distribution Agreement"), to market, distribute and sell the Company's products in the United States, including the District of Columbia.
- In March 2025, we mutually terminated our non-exclusive distribution agreement with MWI.   We entered into a Distribution Services Agreement (the "Agreement") with Covetrus on December 18, 2023.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MRAI | Marpai, Inc. | USD 2.37 | ▲ 26.74% |
| STRN | SMART Trend 25 ETF | USD 26.23 | ▼ 2.92% |
| CNTX | Context Therapeutics Inc. | USD 0.61 | ▲ 0.18% |
| NTRB | Nutriband Inc. | USD 2.98 | ▼ 2.3% |
| PTPI | Petros Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:36 UTC. This page is informational and not investment advice.